Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.

Cytochromes P450 (P450s) play a major role in the clearance of drugs, toxins, and environmental pollutants. Additionally, metabolism by P450s can result in toxic or carcinogenic products. The metabolism of pharmaceuticals by P450s is a major concern during the design of new drug candidates. Determining the interactions between P450s and compounds of very diverse structures is complicated by the variability in P450-ligand interactions. Understanding the protein structural elements and the chemical attributes of ligands that dictate their orientation in the P450 active site will aid in the development of effective and safe therapeutic agents. The goal of this review is to describe P450-ligand interactions from two perspectives. The first is the various structural elements that microsomal P450s have at their disposal to assume the different conformations observed in X-ray crystal structures. The second is P450-ligand dynamics analyzed by NMR relaxation studies.

[1]  David A. Flockhart,et al.  The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[2]  A. Rettie,et al.  Cytochrome P450 2C8: Substrates, Inhibitors, Pharmacogenetics, and Clinical Relevance , 2005, Clinical pharmacology and therapeutics.

[3]  C. Rienstra,et al.  Magic-angle spinning solid-state NMR spectroscopy of nanodisc-embedded human CYP3A4. , 2007, Biochemistry.

[4]  P. Beaune,et al.  Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues , 2007, Pharmacogenetics and genomics.

[5]  P. Ortiz de Montellano,et al.  Ligand-induced conformational heterogeneity of cytochrome P450 CYP119 identified by 2D NMR spectroscopy with the unnatural amino acid (13)C-p-methoxyphenylalanine. , 2008, Journal of the American Chemical Society.

[6]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[7]  L. Waskell,et al.  Threonine-205 in the F Helix of P450 2B1 Contributes to Androgen 16β-Hydroxylation Activity and Mechanism-Based Inactivation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[8]  Raymond A. Dwek,et al.  Nuclear Magnetic Resonance in Biochemistry: Applications to Enzyme Systems , 1973 .

[9]  Frank E. Blaney,et al.  Crystal Structure of Human Cytochrome P450 2D6* , 2005, Journal of Biological Chemistry.

[10]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[11]  W. Tan,et al.  Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. , 2003, Cancer research.

[12]  R. Obach,et al.  Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8 , 2005, Journal of clinical pharmacology.

[13]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[14]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[15]  F. Guengerich,et al.  Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.

[16]  S. Wrighton,et al.  Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. , 1995, Biochemical pharmacology.

[17]  B. Ring,et al.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[18]  J. Vervoort,et al.  1H NMR T 1 relaxation rate study on substrate orientation of fluoromethylanilines in the active sites of microsomal and purified cytochromes P450 1A1 and 2B1 , 1995, FEBS letters.

[19]  B. K. Muralidhara,et al.  Structural and thermodynamic consequences of 1-(4-chlorophenyl)imidazole binding to cytochrome P450 2B4. , 2007, Biochemistry.

[20]  Chris de Graaf,et al.  Cytochrome p450 in silico: an integrative modeling approach. , 2005, Journal of medicinal chemistry.

[21]  Ismael Zamora,et al.  CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors. , 2007, Journal of medicinal chemistry.

[22]  Marie M. Ahlström,et al.  Characterization of type II ligands in CYP2C9 and CYP3A4. , 2008, Journal of medicinal chemistry.

[23]  T. Tracy,et al.  Atypical kinetic profiles in drug metabolism reactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[24]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an NMR study. , 1997, Biochemistry.

[25]  J. Bloomer,et al.  Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. , 1994, Chemical research in toxicology.

[26]  D. Lewis,et al.  Cytochromes P450 in the bioactivation of chemicals. , 2004, Current topics in medicinal chemistry.

[27]  P. Gannett,et al.  Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. , 2004, Biochemistry.

[28]  Ortiz de Montellano,et al.  Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .

[29]  S. Shimotakahara,et al.  Application of NMR screening techniques for observing ligand binding with a protein receptor , 2005, Magnetic resonance in chemistry : MRC.

[30]  S. Rodenhuis,et al.  Clinical Pharmacokinetics of Cyclophosphamide , 1979, Clinical pharmacokinetics.

[31]  Ismael Zamora,et al.  Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors , 2002, J. Comput. Aided Mol. Des..

[32]  M. Sundström,et al.  Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water* , 2000, Journal of biomolecular NMR.

[33]  J. Halpert,et al.  Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Cameron,et al.  Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study. , 2005, Biochemistry.

[35]  J. Halpert,et al.  Interconversion of the androstenedione hydroxylase specificities of cytochromes P450 2B4 and 2B5 upon simultaneous site-directed mutagenesis of four key substrate recognition residues. , 1996, Archives of biochemistry and biophysics.

[36]  Ken-Ichi Fujita.  FOOD-DRUG INTERACTIONS VIA HUMAN CYTOCHROME P450 3A (CYP3A) , 2004, Drug metabolism and drug interactions.

[37]  I. Fleming.  Cytochrome P450 epoxygenases as EDHF synthase(s). , 2004, Pharmacological research.

[38]  A. Cederbaum,et al.  CYP2E1 and oxidative liver injury by alcohol. , 2008, Free radical biology & medicine.

[39]  U. Yasar,et al.  Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation , 2003, The Pharmacogenomics Journal.

[40]  T. Baillie,et al.  Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. , 1999, Chemical research in toxicology.

[41]  E. Johnson,et al.  Positive effectors of the binding of an active site-directed amino steroid to rabbit cytochrome P-450 3c. , 1988, The Journal of biological chemistry.

[42]  D E McRee,et al.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.

[43]  James R. Halpert,et al.  An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Hecht,et al.  Metabolic activation of the tobacco carcinogen 4-(methylnitrosamino)-(3-pyridyl)-1-butanone by cytochrome P450 2A13 in human fetal nasal microsomes. , 2005, Chemical research in toxicology.

[45]  J. Feely,et al.  Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors , 2002, Clinical pharmacokinetics.

[46]  E. Scott,et al.  Structures of Human Cytochrome P-450 2E1 , 2008, Journal of Biological Chemistry.

[47]  J. Halpert,et al.  Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. , 2001, Current drug metabolism.

[48]  R. Tukey,et al.  Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. , 1994, Biochemical pharmacology.

[49]  T. Myers,et al.  Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. , 1994, Journal of Medicinal Chemistry.

[50]  D. Mansuy,et al.  Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. , 1994, Biochemistry.

[51]  B. Meyer,et al.  Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. , 2001, Journal of the American Chemical Society.

[52]  I. Kapetanovic,et al.  Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[53]  J. Halpert,et al.  Analysis of Differential Substrate Selectivities of CYP2B6 and CYP2E1 by Site-Directed Mutagenesis and Molecular Modeling , 2003, Journal of Pharmacology and Experimental Therapeutics.

[54]  Eric F. Johnson,et al.  Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. , 2004, Biochemistry.

[55]  M. Schwab,et al.  Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. , 2007, Pharmacogenomics.

[56]  P. Neuvonen,et al.  Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[57]  K Chiba,et al.  Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  Jozef Hritz,et al.  Impact of plasticity and flexibility on docking results for cytochrome P450 2D6: a combined approach of molecular dynamics and ligand docking. , 2008, Journal of medicinal chemistry.

[59]  Timothy S Tracy,et al.  Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. , 2003, Archives of biochemistry and biophysics.

[60]  F. Guengerich,et al.  Cytochrome P450 activation of arylamines and heterocyclic amines. , 2005, Annual review of pharmacology and toxicology.

[61]  I. Uchiyama,et al.  Identification of cytochrome P450 isoforms involved in 1-hydroxylation of pyrene. , 2004, Environmental research.

[62]  Relly Brandman,et al.  Two-dimensional NMR and All-atom Molecular Dynamics of Cytochrome P450 CYP119 Reveal Hidden Conformational Substates* , 2010, The Journal of Biological Chemistry.

[63]  M. Caggana,et al.  Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. , 2002, The Journal of pharmacology and experimental therapeutics.

[64]  T. Sjögren,et al.  Structural basis for ligand promiscuity in cytochrome P450 3A4 , 2006, Proceedings of the National Academy of Sciences.

[65]  G J Kleywegt,et al.  Detection, delineation, measurement and display of cavities in macromolecular structures. , 1994, Acta crystallographica. Section D, Biological crystallography.

[66]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[67]  Allan B. Okey,et al.  Role of Aryl Hydrocarbon Receptor-mediated Induction of the CYP1 Enzymes in Environmental Toxicity and Cancer* , 2004, Journal of Biological Chemistry.

[68]  P. Gannett,et al.  Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone. , 2008, Archives of biochemistry and biophysics.

[69]  James R. Halpert,et al.  Structure of Microsomal Cytochrome P450 2B4 Complexed with the Antifungal Drug Bifonazole , 2006, Journal of Biological Chemistry.

[70]  C. Stout,et al.  Structure of the Human Lung Cytochrome P450 2A13* , 2007, Journal of Biological Chemistry.

[71]  Eric F. Johnson,et al.  Structure of Mammalian Cytochrome P450 2B4 Complexed with 4-(4-Chlorophenyl)imidazole at 1.9-Å Resolution , 2004, Journal of Biological Chemistry.

[72]  Chris de Graaf,et al.  Metabolic regio- and stereoselectivity of cytochrome P450 2D6 towards 3,4-methylenedioxy-N-alkylamphetamines: in silico predictions and experimental validation. , 2005, Journal of medicinal chemistry.

[73]  W. Jahnke,et al.  Time efficient detection of protein–ligand interactions with the polarization optimized PO-WaterLOGSY NMR experiment , 2009, Journal of biomolecular NMR.

[74]  D. Lewis,et al.  Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[75]  David F. V. Lewis,et al.  Structure–activity relationship for human cytochrome P450 substrates and inhibitors , 2002, Drug metabolism reviews.

[76]  W U Primrose,et al.  A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. , 1996, Biochemistry.

[77]  J. Halpert,et al.  Probing the active site of cytochrome P450 2B1: metabolism of 7-alkoxycoumarins by the wild type and five site-directed mutants. , 1998, Biochemistry.

[78]  Hongbing Wang,et al.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. , 2008, Current drug metabolism.

[79]  N. Benowitz,et al.  Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. , 1992, Chemical research in toxicology.

[80]  M. J. Coon,et al.  Multiple activated oxygen species in P450 catalysis: contributions To specificity in drug metabolism. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[81]  Xinxin Ding,et al.  Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. , 2003, Annual review of pharmacology and toxicology.

[82]  Eric F. Johnson,et al.  The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.

[83]  W. Atkins,et al.  Cooperative binding of acetaminophen and caffeine within the P450 3A4 active site. , 2007, Chemical research in toxicology.

[84]  M. Bowman,et al.  NMR studies of ligand binding to P450(eryF) provides insight into the mechanism of cooperativity. , 2006, Biochemistry.

[85]  C David Stout,et al.  Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen , 2005, Nature Structural &Molecular Biology.

[86]  J. Wiśniewska-Knypl,et al.  The rate of aniline metabolism in vivo in rats exposed to aniline and drugs. , 1975, Xenobiotica; the fate of foreign compounds in biological systems.

[87]  Eric F. Johnson,et al.  Determinants of Cytochrome P450 2C8 Substrate Binding , 2008, Journal of Biological Chemistry.

[88]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[89]  J. Idle,et al.  Polymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates , 2004, Drug metabolism reviews.

[90]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[91]  Yuko Ito,et al.  Structural modelling of the human drug-metabolizing cytochromes P450. , 2006, Current medicinal chemistry.

[92]  D. Sem,et al.  13C-Methyl isocyanide as an NMR probe for cytochrome P450 active sites , 2009, Journal of biomolecular NMR.

[93]  E. Molden.  Variability in Cytochrome P450-Mediated Metabolism of Cardiovascular Drugs: Clinical Implications and Practical Attempts to Avoid Potential Problems , 2004, Heart Drug.

[94]  Eric F. Johnson,et al.  Structural insight into the altered substrate specificity of human cytochrome P450 2A6 mutants. , 2007, Archives of biochemistry and biophysics.

[95]  Xiaodong Zhang,et al.  Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. , 2006, Journal of medicinal chemistry.

[96]  T. Tracy,et al.  Studying cytochrome P450 kinetics in drug metabolism , 2008 .

[97]  Gabriele Cruciani,et al.  Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. , 2003, Journal of medicinal chemistry.

[98]  S. Nelson,et al.  Orientation of caffeine within the active site of human cytochrome P450 1A2 based on NMR longitudinal (T1) relaxation measurements. , 2000, Archives of biochemistry and biophysics.

[99]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[100]  Stephanie C Huelga,et al.  Crystal Structure of a Cytochrome P450 2B6 Genetic Variant in Complex with the Inhibitor 4-(4-Chlorophenyl)imidazole at 2.0-Å Resolution , 2010, Molecular Pharmacology.

[101]  Y. Yamanaka,et al.  Metabolism of methamphetamine, amphetamine and p-hydroxymethamphetamine by rat-liver microsomal preparations in vitro. , 1984, Xenobiotica; the fate of foreign compounds in biological systems.

[102]  C David Stout,et al.  Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an induced fit model of substrate binding. , 2003, Biochemistry.

[103]  H. Vainio,et al.  Enhancement of aniline p-hydroxylation by acetone in rat liver microsomes. , 1972, Xenobiotica; the fate of foreign compounds in biological systems.

[104]  Ismael Zamora,et al.  CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites. , 2007, Journal of medicinal chemistry.

[105]  J. Halpert,et al.  Crystal structures of cytochrome P450 2B4 in complex with the inhibitor 1-biphenyl-4-methyl-1H-imidazole: ligand-induced structural response through alpha-helical repositioning. , 2009, Biochemistry.

[106]  C David Stout,et al.  Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes. , 2003, Biochemistry.

[107]  W U Primrose,et al.  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. , 1997, Biochemistry.

[108]  C David Stout,et al.  Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2*♦ , 2007, Journal of Biological Chemistry.

[109]  S. C. Armstrong,et al.  Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. , 2003, Psychosomatics.

[110]  S. Pochapsky,et al.  Solution NMR structure of putidaredoxin-cytochrome P450cam complex via a combined residual dipolar coupling-spin labeling approach suggests a role for Trp106 of putidaredoxin in complex formation. , 2008, Journal of molecular biology.

[111]  D. Koop,et al.  Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. , 1993, The Journal of biological chemistry.

[112]  E. Scott,et al.  Key Residues Controlling Phenacetin Metabolism by Human Cytochrome P450 2A Enzymes , 2008, Drug Metabolism and Disposition.

[113]  J. Halpert,et al.  Structure-function analysis of human cytochrome P-450 2B6 using a novel substrate, site-directed mutagenesis, and molecular modeling. , 1999, The Journal of pharmacology and experimental therapeutics.

[114]  F. Guengerich,et al.  WHAT MAKES P450s WORK? SEARCHES FOR ANSWERS WITH KNOWN AND NEW P450s* , 2000, Drug metabolism reviews.

[115]  J. Goldstein,et al.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.

[116]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[117]  M. Tarbit,et al.  Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[118]  B. Blaauboer,et al.  Formation and disposition of N-hydroxylated metabolites of aniline and nitrobenzene by isolated rat hepatocytes. , 1983, Xenobiotica; the fate of foreign compounds in biological systems.

[119]  S. Pochapsky,et al.  A model for effector activity in a highly specific biological electron transfer complex: the cytochrome P450(cam)-putidaredoxin couple. , 2003, Biochemistry.

[120]  R. Subramanian,et al.  Effects of fibrates on metabolism of statins in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[121]  M. Aitkin,et al.  Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. , 1999, Pharmacogenetics.

[122]  Surendra S. Negi,et al.  Conformational Flexibility of Mammalian Cytochrome P450 2B4 in Binding Imidazole Inhibitors with Different Ring Chemistry and Side Chains , 2006, Journal of Biological Chemistry.

[123]  N. Vermeulen,et al.  Relationship between paracetamol binding to and its oxidation by two cytochromes P-450 isozymes--a proton nuclear magnetic resonance and spectrophotometric study. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.

[124]  Eric F. Johnson,et al.  Sulfaphenazole derivatives as tools for comparing cytochrome P450 2C5 and human cytochromes P450 2Cs: identification of a new high affinity substrate common to those enzymes. , 2003, Biochemistry.

[125]  D. Lewis,et al.  An evaluation of ondansetron binding interactions with human cytochrome P450 enzymes CYP3A4 and CYP2D6. , 2010, Drug metabolism letters.

[126]  Carrie M. Mosher,et al.  CYP2C9 Genotype-Dependent Effects on in Vitro Drug-Drug Interactions: Switching of Benzbromarone Effect from Inhibition to Activation in the CYP2C9.3 Variant , 2005, Molecular Pharmacology.

[127]  C David Stout,et al.  Structure of Human Microsomal Cytochrome P450 2C8 , 2004, Journal of Biological Chemistry.

[128]  P. Beaune,et al.  Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.

[129]  Jose A G Agundez,et al.  Cytochrome P450 gene polymorphism and cancer. , 2004, Current drug metabolism.

[130]  M. Balazy,et al.  Cytochrome P450/NADPH-dependent biosynthesis of 5,6-trans-epoxyeicosatrienoic acid from 5,6-trans-arachidonic acid. , 2005, The Biochemical journal.

[131]  Louis Leung,et al.  Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism , 2010, J. Comput. Aided Mol. Des..